Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC‐0449). (August 2014)

• Record Type: Journal Article
• Authors: Meani, Rowena E; Lim, Shueh‐Wen; Chang, Anne Lynn S; Kelly, John W
• Is Part Of: Australasian journal of dermatology. Volume 55:Number 3(2014:Aug.)
• Page Start: 218
• Page End: 221
• Publication Date: 2014-08
• Subjects: Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.12196
• Languages: English
• ISSNs: 0004-8380

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p>Vismodegib (GDC‐0449, Genentech, USA), a small molecule inhibitor of the Hedgehog signalling pathway, has potent anti‐tumour activity in advanced basal cell carcinoma (BCC). We report a case of a 67‐year‐old Australian man with metastatic BCC including pulmonary disease with malignant effusion who showed a dramatic complete response to vismodegib but subsequently experienced a recurrence of pulmonary disease, indicative of chemoresistance to vismodegib. This case is the first to illustrate chemoresistance in a patient with metastatic BCC, and demonstrates the need for closely monitoring metastatic BCC patients even after an apparently complete response.</p> </abstract>